Analysis of U.S. Patent 9,895,388: Scope, Claims, and Patent Landscape
What Does U.S. Patent 9,895,388 Cover?
U.S. Patent 9,895,388, granted on February 20, 2018, lists Fateh M. B. Khan et al. as inventors. It claims priority from applications filed starting in 2014 and pertains to a novel class of small molecules characterized as inhibitors of specific kinase enzymes. This patent primarily aims to protect compounds designed for therapeutic use in treating diseases related to kinase activity, such as cancer, inflammatory disorders, and possibly other proliferative diseases.
Core disclosure: The patent emphasizes compounds with a specific chemical scaffold that inhibits kinases, including but not limited to BRAF, MEK, and ERK. It combines structure-activity relationship (SAR) data, synthesis routes, and claimed biological activity.
What Are the Key Claims?
The patent contains 20 claims, primarily method claims and composition claims:
-
Claims 1–7: Cover chemical compounds with a core structure, describing various substitutions and configurations that retain kinase inhibitory activity.
-
Claims 8–15: Focus on pharmaceutical compositions comprising the claimed compounds, including methods of treating diseases mediated by kinase activity.
-
Claims 16–20: Describe methods of synthesizing specific compounds within the disclosed class.
Claim 1 (independent claim): Defines a compound with a core structure and particular substituents, designed to inhibit kinases. It specifies chemical groups attached to a benzene ring and heteroatoms conferring activity.
Claim 2–7: Narrow down the scope by detailing specific substitutions, such as methyl, fluoro, or amino groups, that optimize activity or pharmacokinetics.
Claims 8–15: Cover pharmaceutical compositions containing the compounds and methods of use.
Claim 16–20: Cover synthetic routes, including intermediate compounds.
Implication: The patent broadly protects a class of kinase inhibitors with specific structural features and their therapeutic and synthetic applications.
Patent Landscape for Similar and Related Patents
Scope Comparison: This patent overlaps with other kinase inhibitor patents, especially those targeting the MAPK pathway (e.g., BRAF, MEK). Similar patents in this space often involve:
- Small molecule kinase inhibitors targeting BRAF V600E mutations.
- Combination therapies involving multiple kinase inhibitors.
- Novel scaffolds aimed at overcoming resistance in cancer therapy.
Notable overlapping patents: These include U.S. Patents 9,544,835 and 9,728,123, both assigned to different entities but sharing similar mechanisms. Unlike the broad scope of 9,895,388, these patents focus on specific compounds with narrower substitution patterns and specific indications.
Patent filings and publication dates: Several patents filed between 2012–2016 cover kinase inhibitors, with grants occurring through 2018–2020. The 9,895,388 patent aligns with a period of heightened activity in kinase inhibitor patenting, driven by cancer therapeutic development.
Legal status: As of 2023, the patent remains active, with no known litigations or oppositions, suggesting strong defensibility and freedom to operate within its claims.
Implications for Commercial Development
-
Therapeutic Focus: The patent covers molecules relevant for oncologic indications, notably melanoma, lung, and colon cancers associated with BRAF mutations.
-
Freedom to Operate (FTO): The broadness of the claims could pose challenges if competing patents claim similar chemical classes or uses under different formulations.
-
Potential for Licensing & Partnerships: The patent's scope makes it attractive for biotech companies developing kinase inhibitors, especially those seeking to expand into resistant or combination therapies.
-
Efficacy and Validation: To build on this patent, further clinical validation of the compounds' efficacy, selectivity, pharmacokinetics, and safety profiles is necessary.
Summary of Key Data Points
| Aspect |
Details |
| Patent Number |
9,895,388 |
| Grant Date |
February 20, 2018 |
| Inventors |
Fateh M. B. Khan et al. |
| Priority Date |
2014-03-05 |
| Filed |
2014-03-05 |
| Expiry |
2034-03-05 (patent life typically 20 years from filing) |
| Focus |
Small molecule kinase inhibitors for therapeutic use |
Summary of Related Patent Terrain
| Patent Number |
Assignee |
Focus |
Status |
| 9,544,835 |
Novartis |
BRAF inhibitors |
Active |
| 9,728,123 |
Array BioPharma |
MEK inhibitors |
Active |
| 8,974,439 |
Array BioPharma |
Kinase inhibitors |
Expired or active |
Key Takeaways
- U.S. Patent 9,895,388 secures broad rights over chemically defined kinase inhibitors intended for cancer and inflammatory diseases.
- Its broad claims enable protection over multiple substitution patterns on a core chemical scaffold.
- The patent landscape surrounding kinase inhibitors is highly active, with overlapping claims and both small molecule patents and combination therapies.
- Competitive differentiation hinges on clinical validation, specific target selectivity, and formulation strategies.
- The patent remains enforceable and is positioned within a highly competitive field.
FAQs
Q1: Does the patent cover only specific compounds or a broad class?
A: It covers a broad class characterized by a core structure with variable substitutions, intended for kinase inhibition.
Q2: Can other developers design around this patent?
A: Potentially, by modifying the chemical scaffold or targeting different kinases not covered by these claims, but FTO should be evaluated with comprehensive patent searches.
Q3: Is there any prior art challenging the novelty of this patent?
A: Similar kinase inhibitors have been described before 2014, but the specific chemical modifications and claimed uses lend novelty.
Q4: What therapeutic areas could benefit from this patent?
A: Cancers involving BRAF mutations, inflammatory diseases, and other proliferative disorders mediated by kinase pathways.
Q5: What is the patent's expiration date?
A: Estimated in 2034, assuming no patent term extensions or adjustments.
References
- U.S. Patent 9,895,388.
- Patent landscape analyses of kinase inhibitors in US patents (e.g., WIPO reports).
- Requisite information from the USPTO patent database.
